Naloxone Hydrochloride

CHEMBL1718 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

363.8 g/mol

LogP

—

Phase

4

This is the hydrochloride salt form of naloxone used for the same opioid overdose reversal indications.

분자량

363.8000 g/mol

TPSA

70.00 Å²

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer Colorectal Cancer

작용 기전

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl

InChI

InChI=1S/C19H21NO4.ClH/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;/h2-4,14,17,21,23H,1,5-10H2;1H/t14-,17+,18+,19-;/m1./s1

Molecular Formula

C19H22ClNO4

HBD / HBA

3 / 5

회전 가능 결합

2

무거운 원자

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This is the hydrochloride salt form of naloxone used for the same opioid overdose reversal indications.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Naloxone Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1718. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5464092. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Naloxone Hydrochloride PillFYI에서

구조

핵심 데이터

분자식: C19H22ClNO4
동의어: 10

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.